Cecile Grootscholten
Overview
Explore the profile of Cecile Grootscholten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1502
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
de Gooyer P, Verschoor Y, van den Dungen L, Balduzzi S, Marsman H, Geukes Foppen M, et al.
Nat Med
. 2024 Sep;
30(11):3284-3290.
PMID: 39278994
Mismatch repair deficiency (dMMR) is found in approximately 15% of non-metastatic colon cancers (CCs) and is characterized by a defective DNA mismatch repair system, resulting in hypermutated and highly immunogenic...
2.
Chalabi M, Verschoor Y, Tan P, Balduzzi S, Van Lent A, Grootscholten C, et al.
N Engl J Med
. 2024 Jun;
390(21):1949-1958.
PMID: 38838311
Background: Mismatch repair-deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of...
3.
Filipe W, Buisman F, Franssen S, Krul M, Grunhagen D, Bennink R, et al.
HPB (Oxford)
. 2024 Apr;
26(7):919-927.
PMID: 38604828
Introduction: This study investigates the incidence of extrahepatic perfusion and incomplete hepatic perfusion at intraoperative methylene blue testing and on postoperative nuclear imaging in patients undergoing hepatic arterial infusion pump...
4.
Verschoor Y, van de Haar J, van den Berg J, van Sandick J, Kodach L, van Dieren J, et al.
Nat Med
. 2024 Mar;
30(5):1499.
PMID: 38448792
No abstract available.
5.
Verschoor Y, van de Haar J, van den Berg J, van Sandick J, Kodach L, van Dieren J, et al.
Nat Med
. 2024 Jan;
30(2):519-530.
PMID: 38191613
Gastric and gastroesophageal junction (G/GEJ) cancers carry a poor prognosis, and despite recent advancements, most patients die of their disease. Although immune checkpoint blockade became part of the standard-of-care for...
6.
IJzerman N, Filipe W, de Bruijn P, Buisman F, van Doorn L, Doornebosch P, et al.
Biomed Pharmacother
. 2023 Apr;
162:114625.
PMID: 37058821
Background: Floxuridine's high hepatic extraction ratio and short elimination half-life allows maximum liver exposure with minimal systemic side-effects. This study attempts to quantify the systemic exposure of floxuridine. Methods: Patients...
7.
van der Sluis K, van Sandick J, van Dieren J, Vollebergh M, Grootscholten C, van den Berg J, et al.
Histopathology
. 2023 Jan;
82(6):826-836.
PMID: 36694277
Background And Aims: In gastric cancer (GC), HER2 was the first biomarker for guided therapy registered for clinical use. Considering the recent approvals of immune check-point blockade (ICB) in gastro-oesophageal...
8.
Slagter A, Caspers I, van Grieken N, Walraven I, Lind P, Meershoek-Klein Kranenbarg E, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740628
(1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the...
9.
Voncken F, Vegt E, van Sandick J, van Dieren J, Grootscholten C, Bartels-Rutten A, et al.
Strahlenther Onkol
. 2021 Apr;
197(9):791-801.
PMID: 33825916
Purpose: Respiratory-induced motion of oesophageal tumours and lymph nodes can influence positron-emission tomography/computed tomography (PET/CT). The aim was to compare standard three-dimensional (3D) and motion-compensated PET/CT regarding standardized uptake value...
10.
Kelly R, Ajani J, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al.
N Engl J Med
. 2021 Mar;
384(13):1191-1203.
PMID: 33789008
Background: No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer. Methods: We conducted...